FDA accepts Dupixent (dupilumab) for priority review in adults with prurigo nodularis Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and.
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
/PRNewswire/ Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months.